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Summary
Bioluminescence imaging (BLI) has emerged as a
powerful new method to analyse infectious diseases
in animal models. BLI offers real-time monitoring of
spatial and temporal progression of infection in the
same animal, as opposed to euthanizing a cohort of
animals and quantifying colony or plaque forming
units at multiple time points. Pathogens or mice are
engineered to express genetically encoded luciferase
enzymes from bacteria, insects, or the sea pansy. The
seminal study showing the feasibility of detecting
microbially generated luminescence within a living
mouse was published by Contag and colleagues in
1995, using Salmonella typhimurium transformed
with the lux operon from Photorhabdus luminescens.
Following this, they and others performed many
studies of infection by bioluminescent Gram-negative
and Gram-positive bacteria. Viruses can also be engi-
neered to encode luciferase. Our laboratory has used
bioluminescent reporter viruses to follow HSV and
vaccinia pathogenesis; others have used an alphavi-
rus or novirhabdovirus. Recently, even eukaryotic
parasites Plasmodium, Leishmania and Toxoplasma
have been transformed with luciferase and yielded
unique insights into their in vivo behaviour. We
expect that both the range of organisms and the
molecular events able to be studied by BLI will con-
tinue to expand, yielding important insights into
mechanisms of pathogenesis.
Introduction
Conventional assays of host–pathogen interactions re-
quire that experimental animals be euthanized at multiple
time points to identify sites of infection and quantify
amounts of pathogen in various anatomic sites. While this
approach has defined key aspects of microbial pathogen-
esis, there are important limitations with this conventional
approach to animal models of infection. Analysing indi-
vidual animals at single time points precludes real-time
monitoring of spatial and temporal progression on infec-
tion in the same animal, which may reveal biologically
relevant variations in host–pathogen interactions. Spread
of a pathogen to an unexpected site of infection may be
missed because the infected tissue is not harvested and
analysed. Finally, conventional assays of pathogenesis
typically require large numbers of animals to obtain sta-
tistically meaningful data at multiple time points.
Recently, in vivo imaging techniques have emerged as a
powerful complement to conventional assays of microbial
pathogenesis. In particular, there is increasing use of biolu-
minescence imaging (BLI) to monitor disease processes in
living animals. This technology allows specific molecular
and cellular events, such as cell migration, signal transduc-
tion, proliferation and apoptosis, to be investigated in the
context of an intact animal. In this review, we describe the
technology used for BLI, strengths and limitations of this
technique, and potential future applications in small animal
models of microbial pathogenesis.
Bioluminescence imaging reporter enzymes
Bioluminescence imaging detects light produced by the
reaction of luciferase enzymes with a defined substrate.
There are two different strategies for engineering biolumi-
nescent reporters in pathogens or host cells. First, the lux
operon from bacteria such as Photorhabdus luminescens
or Xenorhabdus luminescens encodes genes to syn-
thesize luciferase and the substrate luciferin. Bacteria
expressing the lux operon constitutively produce light
without the need for an exogenous substrate. The lux
operon has been transferred stably to other species of
bacteria for imaging studies. However, this operon has not
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been transferred to higher species, although there are
ongoing efforts to engineer the lux operon as a reporter
system for mammalian cells.
The second strategy for bioluminescent reporters uses
luciferase enzymes from organisms such as the firefly
(Photinus pyralis) or sea pansy (Renilla reniliformis).
Pathogens and mammalian cells can be engineered to
express one or more luciferase enzymes as reporters for
in vivo imaging. Mammalian tissues do not produce the
luciferin or coelenterazine substrates for firefly or Renilla
luciferases, respectively, so these molecules must be
delivered systemically for small animal imaging. Luciferin
rapidly distributes throughout a mouse and penetrates
intact blood–tissue barriers, such as the placenta and
brain, after intraperitoneal injection. Therefore, substrate
availability is not a limitation for in vivo imaging with firefly
luciferase. By comparison, bioavailability of coelentera-
zine, the substrate for Renilla luciferase, is limited in vivo,
at least in part by the multidrug resistance P-glycoprotein
(MDR1), which transports coelenterazine and similarly
structured compounds out of or off the membranes of
mammalian cells (Pichler et al., 2004). Thus, coelentera-
zine may be unavailable to the cytoplasm of some cells
infected with a Renilla luciferase-expressing virus, and
may also have difficulty crossing membranes.
Because firefly and Renilla luciferase use two different
substrates, it is possible to use these reporters to image
two different biological processes in the same mouse
(Bhaumik and Gambhir, 2002). However, the kinetics of
each reporter differ markedly, in part because of differ-
ences in pharmacokinetics of each substrate. After intra-
peritoneal injection of luciferin, bioluminescence from
firefly luciferase reaches a plateau in approximately
10 min and remains relatively constant up to 30 min
(Paroo et al., 2004). Bioluminescence from Renilla
luciferase peaks rapidly at 1 min after intravenous injec-
tion of coelenterazine and then declines to near back-
ground levels by 10 min (Bhaumik and Gambhir, 2002).
It also is possible to distinguish two unique biological
processes based on differences in emission spectra of
various luciferases. Renilla luciferase and the bacterial lux
operon luciferase have peak emissions at 480 and
490 nm respectively. Using appropriate wavelength filters,
light from these enzymes can be distinguished from firefly
luciferase, which emits at approximately 560 nm, or other
red-shifted click beetle luciferases. This type of strategy is
described below for imaging bacterial localization and a
host response. An important caveat for multireporter
studies is the greater attenuation of light from blue-green
luciferases (Renilla and bacterial) relative to firefly
luciferase or other enzymes that emit light greater than
600 nm. As a result, in vivo detection of Renilla or bacte-
rial luciferase is much less sensitive than enzymes with
red-shifted emission spectra.
Bioluminescence imaging instrumentation and
imaging technique
Instruments for BLI use a very sensitive charge-coupled
device (CCD) camera to detect the low levels of light
emitted from luciferase reporters in vivo. There is minimal
background from with this technique, although mouse
chow containing chlorophyll or similar pigments can
produce low amounts of light in the intestine. Because of
the very low background signal, it is possible to detect
relatively small numbers of a pathogen in mouse models.
For example, we have shown that ocular infection with a
bioluminescent Herpes simplex virus type 1 reporter virus
(HSV-1) can be detected at an input titre as low as 1 ¥ 102
plaque-forming units (pfu) (Luker et al., 2002). BLI is a
rapid and relatively inexpensive imaging modality that
allows large numbers of mice to be examined repetitively.
In our experience, approximately 20–30 mice can be
imaged in approximately 1 h. Bioluminescence can be
measured by computer analysis of emitted photons,
allowing relative quantification of data. Assuming that
expression of the luciferase enzyme is maintained by the
engineered pathogen or cell, relative numbers of viruses,
bacteria, or cells correlate directly with greater biolumi-
nescence. However, absolute values for bioluminescence
produced by a defined number of pathogens will differ in
various anatomic sites because of absorption and scat-
tering of light by overlying tissues.
Although BLI is the most commonly used imaging tech-
nique for studying pathogenesis, there are important limi-
tations to this modality. In addition to 10-fold attenuation of
light by overlying tissues, bioluminescence is decreased
by pigmentation of organs, such as liver and spleen, and
fur. This affects studies of viral-host pathogenesis
because many genetically engineered mice are devel-
oped in SV129 or C57BL/6 backgrounds. Shaving mice
with electric clippers and removing fur with a depilatory
agent (such as Nair) can minimize this problem. Alterna-
tively, mice can be bred into an albino C57BL/6
background. BLI typically is a two-dimensional imaging
technique with a spatial resolution of 2–3 mm, although
there are three-dimensional imaging system and/or
reconstruction techniques available commercially. Even
with advanced instrumentation, it still may be difficult to
separate photons produced by infected cells in two imme-
diately adjacent sites, such as the eye and periocular
tissues. Finally, although BLI is a powerful imaging modal-
ity in small animal models, it is unlikely to be used in
humans because of the limitations in detecting light pro-
duced in deep tissues.
Validation of BLI for bacterial pathogenesis
Initial studies showing the feasibility of BLI for studying
microbial pathogenesis were performed by Contag and
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colleagues (Contag et al., 1995). These researchers
stably transformed three strains of Salmonella typhi-
murium with a plasmid bearing the lux operon from
P. luminescens (luxCDABE). Luminescent bacteria were
detected throughout C57BL/6 or BALB/c mice following
infection, showing that the bioluminescent reporter signal
could be detected in vivo. As evidence that BLI could be
used for serial studies of bacterial pathogenesis, imaging
was used to monitor bacterial distribution, distinguish
between more and less virulent strains of bacteria, differ-
entiate susceptibility of mouse strains to infection, and
monitor antibiotic therapy. This initial study also high-
lighted the importance of oxygen for light produced by the
lux operon. While there is sufficient oxygen in viable mam-
malian tissues to support the luciferase reaction, the
ability of BLI to detect extracellular bacteria in anaerobic
microenvironments, such as the lumen of the intestine,
may be limited. Indeed, injection of air into the ileum and
colon of Salmonella-infected mice caused the appear-
ance of a luminescent signal where none previously had
been detectable.
Further work validating BLI for monitoring bacterial
infection was carried out by a different group a few years
later (Rochetta et al., 2001). They set out to test, rigor-
ously and with statistical analysis, whether BLI could be
used to measure antibiotic efficacy in vitro and in vivo,
using luxCDABE-transformed E. coli. They found that BLI
could be used to reliably determine minimal inhibitory
concentrations (MIC) and minimal bactericidal concentra-
tions (MBC) of antibiotics in broth culture. Growth curves
generated by BLI correlated with curves generated by
plating and counting colony-forming units (cfu). BLI mea-
surements correlated very highly (r = 0.98) with colony
counts for dose-dependent responses to three different
antibiotics in vitro. This correlation extended to in vivo
imaging in a soft tissue model of infection, where dose-
dependent inhibition of bacterial growth with ceftazidime
was quantified with BLI and colony counts. However,
there were also differences in the magnitude of inhibition
as measured by BLI or colony counts, which varied
according to the time point and the drug being used. The
study noted that BLI-generated curves increased or
decreased more consistently than curves generated using
traditional colony counts. The authors attributed this to the
fact that sequential luminescence points are derived from
the exact same set of animals, while cfu are derived from
different groups of animals. These data demonstrate an
advantage of in vivo imaging for quantifying responses to
treatment in the same cohort of mice over time.
More recently, another study compared light from lux
CDABE-transformed Pseudomonas aeruginosa with
the conventional colony counts in a model biofilm
(Marques et al., 2005). After treatment with ciprofloxacin,
these authors found a discrepancy between cfu and
bioluminescence. Cfu from the disrupted film decreased
to a much greater degree than light intensity from the
same biofilm, and the kinetics of recovery after cessation
of antibiotic were different between the two methods.
They offer several possible explanations for these find-
ings, including elongation of drug-injured cells resulting
in greater light output per cell and differential effects of
ciprofloxacin on light-producing ability versus viability.
They conclude that ‘bioluminescence and viable counts
measure different aspects of cell physiology and neither
should be regarded as the definitive indicator of cell
viability.
Bioluminescence imaging in bacterial pathogenesis
Following the initial proof-of principle study for BLI in
bacterial pathogenesis, this technology has been used to
study a variety of other bacterial pathogens. As evidenced
by many different publications, BLI has allowed research-
ers to identify new features of host–pathogen interactions.
Representative examples of BLI applications in bacterial
infection are described below.
Wiles and colleagues transformed Citrobacter with a
transposon plasmid to stably integrate the luxCDABE
operon into the bacterial genome (Wiles et al., 2004).
After confirming that the transformed bacteria were not
attenuated in vivo or in vitro compared with the parent
strain, they orally inoculated mice with the bioluminescent
Citrobacter and monitored colonization and clearance of
the mouse colon by BLI and colony counts. These authors
made the new discoveries that Citrobacter colonized the
caecal patch before colonizing the rest of the colon, and
bacteria were cleared from the caecum before being
cleared from the rest of the colon. Oxygen availability was
not a confounding factor in this study because mice were
dissected and their intestines moved to a Petri dish prior
to imaging. In a subsequent article (Wiles et al., 2005), the
same authors use the luminescent Citrobacter to show
that this bacterium becomes ‘hyperinfectious’ after
passage through a mouse, requiring a lower infectious
dose to colonize naïve mice. In addition, these ‘hyperin-
fectious’ bacteria did not need to colonize the caecal
patch before infecting the rest of the colon.
The P. luminescens luxCDABE operon is not translated
in Gram-positive bacteria such as Staphylococcus aureus
because ribosomes in Gram-positive organisms cannot
bind and translate the mRNA. Early attempts at making
bioluminescent S. aureus relied on firefly luciferase or
variations of a partial lux operon (luxAB), encoding
luciferase only (Corbisier et al., 2004) (Steidler et al.
1996). These approaches have the disadvantages of
requiring the addition of exogenous substrate and deter-
gent or being unstable at temperatures above 30°C (Hill
et al., 1993). This technical challenge was overcome by
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Francis and colleagues, who modified luxCDABE so that
it could be expressed by Gram-positive bacteria (Francis
et al., 2000). This technical advance was accomplished
by constructing a Gram-positive ribosome binding site
(RBS) and inserting it upstream of each gene in the
operon. The new cassette was called luxABCDE. LuxAB-
CDE was used to transform S. aureus. Light emitted
by the transformed S. aureus was bright, was optimal
at 37°C, correlated with colony counts in vitro, and
decreased upon antibiotic treatment in a mouse model of
S. aureus thigh infection. These researchers then devel-
oped a transposon-based method for stably integrating
luxABCDE into the genome of Streptococcus pneumo-
niae (Francis et al. 2001). Genomic DNA from a success-
fully transformed, brightly luminescent transposant was
used to transform clinical isolates of S. pneumoniae. The
transformed isolates were equal in virulence to their
parent strains and allowed BLI imaging of a 7 day course
of infection and response to antibiotic therapy. It was
noted that luminescence dropped sharply when the bac-
teria reached stationary phase in culture, but this phe-
nomenon did not affect in vivo results.
A recent study by Hardy et al. emphasizes the power of
BLI to reveal unexpected new locations of microbial rep-
lication (Hardy et al., 2004). The authors generated bio-
luminescent Listeria monocytogenes carrying luxABCDE
stably integrated into the chromosome. Although the
transformed strain was attenuated compared with the
parent strain, they used a combination of in vivo imaging
and image-guided dissection to show that L. monocyto-
genes can live and probably replicate in the lumen of the
mouse gall bladder, suggesting that it may do the same in
the human gall bladder. Therefore, the gall bladder may
represent an internal reservoir for Listeria.
Finally, a very interesting study of S. pneumoniae
meningitis described the combined use of two different
bioluminescent systems to simultaneously yield data
about bacterial replication and the host response (Kadu-
rugamuwa et al., 2005). The authors used a transgenic
mouse that expressed firefly luciferase under control of
the promoter for glial fibrillary acidic protein (GFAP).
GFAP is an intermediate filament protein expressed by
mature central nervous system (CNS) astrocytes, and it
is an established marker for astrocyte activation. Bio-
luminescent S. pneumoniae were injected into the sub-
arachnoid space of transgenic GFAP-firefly luciferase
mice, and the resulting infection was monitored over
72 h. Bacterial luminescence could be distinguished
from luminescence due to activation of the GFAP pro-
moter because of their differing peak emission wave-
lengths in vivo (490 nm for bacterial luciferase, 610 for
firefly luciferase). The reporter signals also could be dis-
tinguished because the firefly luciferase signal required
the injection of its substrate, luciferin.
The authors found parallel increases in both bacterial
and GFAP signals in infected areas of the brain and spinal
cord. However, the onset of bioluminescence from GFAP
was 3–4 h later than the onset of the bacterial signal. If
infected mice were treated with the antibiotic ceftriaxone,
the bacterial signal decreased to baseline. However,
the effect of antibiotic treatment on the GFAP signal
depended on when the antibiotic was given. If ceftriaxone
was administered 11 h or less post infection, the GFAP
signal never rose above baseline. At 17 h post infection,
the brain GFAP signal was moderately high, and admin-
istration of ceftriaxone eliminated bacteria without affect-
ing the GFAP reporter signal. Furthermore, if ceftriaxone
was delayed until 19 h post infection, the brain GFAP
signal increased 30- to 100-fold. Most of these mice did
not survive beyond 22 h, but those that did sometimes
experienced epileptic seizures. These data suggest that
the host proinflammatory response is a major factor
causing morbidity and mortality in this disease.
While we expect that future studies will exploit this
multicolour strategy to image both a pathogen and host
response, it is important to note the added complexity of
this method. Shorter wavelengths of visible light are
attenuated by tissues to a greater extent than longer
wavelengths. Therefore, less light will be transmitted
from bacterial luciferase (490 nm emission) than firefly
luciferase (610 nm emission), which will affect quantifica-
tion of imaging data. Because bioluminescence images
are weighted towards light emitted at or near the surface
of an animal, there also will be depth-dependent spectral
shifts in the emitted light that can complicate analysis of
data. Despite these caveats, we expect future applica-
tions of multicolour imaging to yield new insights into host
immune responses to other pathogens.
Viral infections
Our laboratory has used BLI to investigate pathogenesis
of HSV-1 infection in mice, using a recombinant strain
KOS virus that encodes both firefly luciferase and Renilla
luciferase under control of an early gene promoter (Luker
et al., 2002). Initial research established that firefly
luciferase activity from the reporter virus could be
detected readily in mice after four different routes of
infection. Viral titres quantified by plaque assay correlated
directly with light emitted from firefly luciferase. This study
also demonstrated limitations of BLI for pathogenesis
studies. Because of the relatively low spatial resolution of
this imaging modality, it is difficult to distinguish between
viral infections in adjacent tissues. For example, biolumi-
nescence from the site of infection in the cornea could not
be separated from subsequent spread of infection to
periocular tissues. In addition, light from firefly luciferase
was detected readily in the infected cornea after intra-
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peritoneal administration of luciferin, but Renilla luciferase
was identified only when coelenterazine was applied
directly to the cornea. The latter finding emphasizes prob-
lems with bioavailability of coelenterazine due to trans-
porters such as MDR1 P-glycoprotein.
We subsequently used this same HSV-1 reporter virus to
further analyse viral-host interactions in mice with BLI. Our
laboratory investigated effects of type I and type II inter-
feron receptors on replication and spread of HSV-1 (Luker
et al., 2003). In wild-type mice and mice lacking receptors
for type II interferons, HSV-1 infection remained localized
to the site of epithelial infection and innervating sensory
neurons. By comparison, we found that type I interferon
signalling is essential to limit systemic dissemination of
HSV-1. In mice lacking receptors for type I interferons,
HSV-1 disseminated from the site of inoculation in cornea
or footpads to infect multiple abdominal organs, including
liver and spleen. This phenotype was exacerbated in mice
lacking both type I and type I and II interferon receptors,
demonstrating the critical function of innate immunity in
restricting HSV-1 dissemination. The presence of abdomi-
nal activity in multiple organs also illustrated a potential
limitation of BLI for anatomic localization. Because the
luminescent image is two-dimensional, the precise origin
of bioluminescence in the abdomen was difficult to discern
from a single image. This problem was largely overcome by
imaging mice at several different projections: dorsal,
ventral and left lateral. Using information from these three
images and knowledge of mouse anatomy, infection was
localized to liver, spleen, kidneys, spine and popliteal
lymph nodes. These sites were confirmed by dissection of
the mice and imaging of isolated organs.
The KOS reporter virus also has been used by Burgos
et al. to monitor intraperitoneal infection with HSV-1
(Burgos et al., 2006). Based on in vivo and ex vivo
imaging of abdominal organs, these authors determined
that ovaries and adrenal glands were the primary sites of
infection in this model. Bioluminescence correlated
directly with amounts of HSV-1 DNA quantified by real-
time polymerase chain reaction (PCR), further validating
the reporter virus for studies of viral replication and spread
in vivo.
As an alternative approach to image HSV-1 infection
with BLI, we engineered a transgenic mouse to respond to
viral infection, rather than expressing firefly luciferase
from the viral genome (Luker et al., 2006). The transgenic
mouse expressed firefly luciferase (FL) under the control
of the promoter HSV-1 thymidine kinase (tk) promoter to
detect viral replication. These mice produced light at the
site of HSV-1 infection, using either corneal or flank
models, but corresponding sites of mock infection did not
(Fig. 1). Light was produced in response to infection with
three different strains of HSV-1, and increasing the viral
inoculum caused a corresponding increase in lumines-
cence intensity. Moreover, no luminescence above back-
ground was seen when the mice were infected with an
unrelated tk-expressing DNA virus. This shows that the
TK-FL mouse could be used to study replication and
spread of HSV-1 specifically.
The advantage of using a reporter mouse instead of a
reporter virus is that multiple strains or mutants of HSV-1
can be studied without making a new recombinant virus
each time. Moreover, this method avoids the possibility
that the virus may be attenuated by inserting a reporter.
However, there also are limitations to the reporter mouse
strategy. First, the reporter mouse is approximately
10-fold less sensitive for detecting HSV-1 infection as
compared with a reporter virus. This may be due to dif-
ferences in number of copies, level of transcription, or
level of translation of the reporter gene when it is inte-
grated into the host genome instead of the virus genome.
Second, the HSV-1 reporter mouse, similar to many other
luciferase reporter animals, has background lumines-
cence in ears, paws and tail, possibly due to the increased
stability of the luciferase protein at cooler temperatures in
the extremities. While this background does not preclude
its use for studying HSV infections in the eye or flank, it
does make it unsuitable for studying infections given in
the footpad. Nevertheless, the TK-FL mouse represents a
novel way to study HSV pathogenesis using BLI.
Our laboratory also has developed bioluminescent and
fluorescent reporter vaccinia viruses for studying poxvirus
infection in vivo with BLI. These reporter viruses are not
attenuated relative to wild-type Western Reserve strain
vaccinia virus in vitro or in vivo, allowing studies of viral
pathogenesis similar to those described for HSV-1. Using
BLI to monitor spatial and temporal progression of viral
infection, we have shown that type I interferons signalling
predominantly in parenchymal, rather than haematopoi-
etic cells, limit systemic dissemination of vaccinia virus




Fig. 1. Reporter mouse for HSV-1 infection. The transgenic mouse
expresses firefly luciferase under the control of the promoter for
HSV-1 thymidine kinase. The uninfected mouse shows background
bioluminescence in the ear (asterisk), which is seen commonly in
firefly luciferase transgenic mice. There is robust activation of the
HSV-1 reporter transgene in the infected eye and periocular tissues
(arrow) 6 days after infection with 1 ¥ 106 pfu strain McKrae HSV-1.
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to identify a protective function for alveolar macrophages
in host defence against respiratory infection with vaccinia
virus (Rivera et al., 2007).
Both HSV-1 and vaccinia virus are DNA viruses with
large genomes that can accommodate insertion of
reporter genes. Insertion of luciferase reporters has been
an obstacle for studies of viruses with RNA genomes,
although BLI has been used to monitor a limited number
of RNA viruses. For example, Cook and Griffin generated
recombinant Sindbis viruses that express firefly luciferase
for studies of viral entry into the CNS. BLI offers two
advantages for addressing this question in the biology of
alphaviruses such as Sindbis. First, Sindbis virus occurs
in significant quantities free in the blood (Cook and Griffin,
2003). When an organ is excised for standard plaque
assays of viral titres, virus in infected tissues cannot be
distinguished from free virus in the vasculature. Because
light is produced only in infected cells, confounding effects
of free virus on measurements of organ infection are
eliminated. However, it is important to realize that light
may be produced by infected leukocytes that remain
within blood vessels. Second, BLI offers real-time moni-
toring of viral dissemination in the same mouse, thereby
allowing serial studies of viral localization. Using a foot
pad model of infection, some mice developed nasal infec-
tion prior to brain infection, while other mice developed
spinal cord infection. The variation between different mice
may be one reason it has been difficult to determine the
route of brain entry for Sindbis virus. One caveat of these
studies is that the recombinant viruses were attenuated
by approximately 50% in mice compared with parental
virus, showing the difficulty in making reporter pathogens
for some RNA viruses.
Bioluminescence imaging typically has been used to
study infection in mouse models, but this imaging modal-
ity can be used effectively in other organisms. For
example, Harmache et al. used BLI to investigate infec-
tion with infectious haematopoietic necrosis virus (IHNV),
an RNA virus that is significant pathogen in young trout
fish (Harmache et al., 2006). In particular, the study
focused on the route of viral entry into fish. To enable this
study, the authors constructed a recombinant IHNV that
expressed a Renilla luciferase reporter. Unlike Sindbis
virus, the recombinant IHNV virus was not attenuated
compared with the parental strain. Juvenile trout were
infected with the reporter virus and then imaged with BLI
at various times post infection. Whole-body luciferase
imaging of infected fish revealed the unexpected localiza-
tion of virus to the fin bases. Infection of fin bases
occurred prior to infection of other organs and tissues and
persisted after virus had spread systemically. Imaging of a
euthanized fish with the skin removed established that
light from inside the body could be detected readily
through the skin, suggesting the early detection of lumi-
nescence in fin bases is not simply due to the thinness of
the tissue at that site. An attenuated virus lacking a non-
structural protein infected the fin bases without dissemi-
nating, which further supported the conclusion that viral
entry occurred through fin bases. This study established
the power of BLI to study infection in non-mouse models
of infection.
Parasites and fungi
Recent studies also demonstrate that BLI can be used to
investigate parasitic infections. Hitziger et al. investigated
analysed virulence of two different strains of biolumines-
cent Toxoplasma gondii (Hitziger et al. 2005). These
authors established a high correlation between light inten-
sity and amounts of parasite in spleen and testis, which is
consistent with findings for other pathogens described
above. They also concluded that deletion of various Toll-
like receptors (TLR1, 2, 4, 6, or 9) did not affect suscep-
tibility of mice to infection with this parasite. Saeij et al.
also engineered luciferase reporter strains of Toxoplasma
and used BLI to quantify differences in replication over
time, as well as imaging reactivation of parasites in the
setting of chronic infection (Saeij et al., 2005). It is impor-
tant to note that Saeij et al. determined that the reporter
strains were slightly attenuated compared with corre-




Fig. 2. Firefly luciferase vaccinia virus. A mouse lacking receptors
for type I and II interferons was infected intranasally with 1 ¥ 106
pfu of a recombinant Western Reserve vaccinia virus engineered to
express firefly luciferase from a hybrid early/late promoter.
Widespread systemic dissemination of virus is seen 5 days after
infection. Viral bioluminescence is evident in the nasopharynx
(arrow), lungs, liver, and inguinal lymph node (asterisk).
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demonstrate that luminescent T. gondii can be engineered
and used to reveal new information about this parasite’s
pathology.
Bioluminescent Leishmania amazonensis and Plasmo-
dium berghei have also been developed and used to
monitor parasitic infection in vivo. Lang et al. generated
firefly luciferase expressing Leishmania and used the
reporter parasite to monitor infection and response to
therapy in cell culture, excised organs from infected mice,
and living mice (Lang et al., 2005). Franke-Fayard and
colleagues (Franke-Fayard et al., 2005) engineered
three firefly luciferase expressing P. berghei: one that
expressed luciferase in all life stages, one that expressed
luciferase under a gametocyte-specific promoter, and one
that expressed luciferase under a schizont-specific
promoter. Using these luminescent parasites, the authors
determined that red blood cells infected with the schizont
stage of the parasite are sequestered in the micro-
vasculature of the lung and adipose tissue. Sequestration
of the parasite is dependent on expression of CD36 on the
capillary endothelium. These authors also demonstrated
that cerebral malaria is not dependent on CD36-mediated
red blood cell sequestration, which countered previous
assumptions of disease pathogenesis. Importantly, the
ability to monitor specific stages in the parasite life cycle is
a key advance for in vivo BLI studies.
The development and use of bioluminescent fungi for
monitoring fungal infections in vivo is less advanced than
for other kinds of pathogens, in part due to technical
challenges with engineering bioluminescent reporter
organisms. One group recently transformed Candida albi-
cans with firefly luciferase stably integrated into the chro-
mosome and use the recombinant fungus as a marker of
mucosal or systemic infection (Doyle et al., 2006a,b).
Fungal bioluminescence was detected easily, and data for
photon flux corresponded with cfu counts in a vaginal
mucosal infection. However, fungal bioluminescence from
systemic infections in intact animals was too dim to corre-
late well with colony counts or to give useful information
about the extent of infection. It was hypothesized that this
is due to a combination of attenuation of light by overlying
tissues and reduced permeability of the hyphal cell wall to
the substrate luciferin compared with the cell wall of the
yeast form. Because yeast are slow-growing compared
with bacteria, the ability to monitor mucosal infections in
real time with BLI potentially can give a significant advan-
tage in drug screens. However, the great attenuation of the
light in systemic infections greatly limits the usefulness of
this bioluminescent Candida to study in vivo pathogenesis.
Future directions. BLI has proven to be a powerful tool
for localizing and quantifying microbial infections in vivo,
establishing that imaging techniques can substantially
advance studies of pathogenesis. In the future, we antici-
pate the development of imaging strategies to detect not
only the pathogen, but also cellular and tissue-wide host
reactions. The study by Kadurugamuwa et al. using mul-
ticolour bioluminescence to interrogate bacterial spread
and host neuronal injury is key step towards the goal of
monitoring both the host and pathogen. Because of the
inherent challenges with multicolour BLI, it is likely that
BLI will be combined with other structural and/or func-
tional imaging methods, such as magnetic resonance
imaging (MRI), radiotracer modalites (positron emission
tomography, PET; single-photon emission computed
tomography, SPECT) or computed tomography (CT).
MRI, PET and SPECT each have been used to analyse
trafficking of immune cells, including T lymphocytes and
dendritic cells, generally in the context of cancer or
autoimmunity. However, these same approaches could be
applied to interrogate kinetics and localization of immune
cells in response to infection.
In addition to imaging defined populations of immune
cells, we envision that small animal imaging methods will
be used to quantify changes in tissue architecture, per-
meability, or metabolism associated with infection. For
example, both MRI and CT can detect sites of inflamma-
tion based on alterations in vascular permeability and/or
tissue water. PET imaging with the glucose analogue 18F-
fluorodeoxyglucose also can be used to detect focal sites
of inflammation during infection, based on increased
metabolism of glucose by infiltrating immune cells. Image
co-registration techniques then can be used to integrate
data from multiple imaging examinations, providing an
integrated data set for the pathogen and specific compo-
nents of host immunity. Through these approaches, we
expect imaging to become a key component of basic and
translational research in infectious disease.
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